In fact, cortactin gene inactivation in endothelial cells counteracts the entry of CD4+ and myeloid cells into the CNS and, consequently, inflammation and demyelination decrease as well as symptoms in EAE, the in vivo model of MS [45]. This evidence concerns the gene CD4 and myeloid sarcoma.